{"id":"W2588777013","doi":"10.1093/annonc/mdw373.16","title":"Interim analysis of a phase I dose escalation trial of ASG-22CE (ASG-22ME; enfortumab vedotin), an antibody drug conjugate (ADC), in patients (Pts) with metastatic urothelial cancer (mUC)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta","funders":"","keywords":"Medicine; Internal medicine; Response Evaluation Criteria in Solid Tumors; Adverse effect; Oncology; Interim analysis; Gastroenterology; Phases of clinical research; Chemotherapy; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003714278,0.001630369,0.002702625,0.0003261219,0.0005140873,0.001627461,0.0006754546,0.001220384,0.00575993],"category_scores_gemma":[0.00290473,0.0005045751,0.002728436,0.0004684232,0.0007680521,0.001187641,0.0004460808,0.003728981,0.001132018],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008095275,"about_ca_system_score_gemma":0.00130468,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005551951,"about_ca_topic_score_gemma":0.001261502,"domain_scores_codex":[0.9988357,0.0005861039,0.00004988863,0.0001589252,0.00008855566,0.000280809],"domain_scores_gemma":[0.9981786,0.0005464558,0.0003500963,0.0002874424,0.0001189796,0.0005184409],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.919984,0.009400019,0.003958683,0.0003923041,0.002590633,0.0001653731,0.0001690119,0.00526903,0.007370688,0.0003953569,0.006030658,0.04427435],"study_design_scores_gemma":[0.5308033,0.4168824,0.02847329,0.00007060262,0.003117022,0.0003565634,0.0001510039,0.005611732,0.004707643,0.001792455,0.007955824,0.00007817958],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9793261,0.003188819,0.002376519,0.001171286,0.0005265585,0.002453391,0.004720372,0.0002974951,0.005939428],"genre_scores_gemma":[0.9805038,0.0009549251,0.002370765,0.001437171,0.0001892669,0.002654921,0.00583672,0.00008938721,0.00596313],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00575993,"threshold_uncertainty_score":0.01964319,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0723208167170428,"score_gpt":0.4419982571152622,"score_spread":0.3696774403982194,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}